Within the SGC Open-Source Target Discovery Partnership, our aim is to define and validate under-explored protein targets by profiling high quality chemical and antibody probes in patient-cell derived assays, providing biomarker, target engagement and phenotypic read-outs from test systems that should more accurately mimic the disease itself. To this end, our tissue platform teams at each site develop test systems based on cells and tissue from patients and healthy controls, using primary cell systems as well as stem cell based approaches.

The current network of collaborations consists of hospitals and universities in Toronto, Montreal (Canada), Oxford (UK) and Karolinska (Sweden), with focus on auto-immune diseases, fibrosis, inflammation, neurodegenerative diseases and oncology.